newsfilter
← Latest News
GlobeNewswire·

LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

• LIBRA trial designed to support registration of TP-03 in China• Topline results expected in the fourth quarter of 2023 SHANGHAI, China and PRINCETON, N.J., June 08, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN),